Y0000297
美沙拉嗪
European Pharmacopoeia (EP) Reference Standard
别名:
5-氨基水杨酸, 5-AS, 5-氨基-2-羟基苯甲酸, 氨水杨酸
等级
pharmaceutical primary standard
API类
mesalamine, mesalazine
制造商/商品名称
EDQM
mp
275-280 °C (dec.) (lit.)
应用
pharmaceutical (small molecule)
包装形式
neat
储存温度
2-8°C
SMILES字符串
Nc1ccc(O)c(c1)C(O)=O
InChI
1S/C7H7NO3/c8-4-1-2-6(9)5(3-4)7(10)11/h1-3,9H,8H2,(H,10,11)
InChI key
KBOPZPXVLCULAV-UHFFFAOYSA-N
基因信息
human ... ALOX5(240), PPARG(5468), PTGS1(5742), PTGS2(5743)
正在寻找类似产品? 访问 产品对比指南
警示用语：
Warning
危险分类
Eye Irrit. 2 - Skin Irrit. 2 - Skin Sens. 1 - STOT SE 3
靶器官
Respiratory system
储存分类代码
11 - Combustible Solids
WGK
WGK 2
闪点(°F)
No data available
闪点(°C)
No data available
Altamash I Qureshi et al.
Advanced drug delivery reviews, 57(2), 281-302 (2004-11-24)
Sulfasalazine's role as the first-line of therapy in patients with inflammatory bowel disease has led to the development of other "designer" aminosalicylates, which eliminate the sulfa-moiety, and attempt to target the topically active mesalamine to the inflamed bowel. Olsalazine sodium
P D R Higgins et al.
Alimentary pharmacology & therapeutics, 29(3), 247-257 (2008-10-24)
Ulcerative colitis (UC) can be maintained in remission with 5-aminosalicylic acid (5-ASA) medications, but frequent non-adherence by patients who are feeling well has been associated with more frequent flares of colitis. To perform a systematic review of the published literature
A H Steinhart et al.
Alimentary pharmacology & therapeutics, 25(12), 1389-1399 (2007-06-02)
To evaluate the effectiveness of pH 6-/pH 7-dependent and controlled-release mesalazines in maintaining medically and surgically induced Crohn's disease remission. A systematic search identified 13 randomized controlled trials (RCTs). The rate of symptomatic relapse (Crohn's disease activity index >150, or
Marietta Iacucci et al.
Canadian journal of gastroenterology = Journal canadien de gastroenterologie, 24(2), 127-133 (2010-02-13)
5-aminosalicylic acid (5-ASA) preparations (eg, mesalazine, mesalamine) are well-established preparations used in the management of inflammatory bowel disease. These drugs are most useful for the treatment of mild to moderate flares of ulcerative colitis and, especially, for maintenance of remission.
Morris Gordon et al.
The Cochrane database of systematic reviews, (1)(1), CD008414-CD008414 (2011-01-21)
The use of 5-aminosalicylates (5-ASAs) in Crohn's disease (CD) is controversial. A recent Cochrane review found that 5-ASAs are not effective for the maintenance of medically-induced remission in CD, but their role in the maintenance of surgically-induced remission is unclear.
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持